Friday, July 18, 2025 7/18/2025

DIGITAL GENE EXPRESSION FOR CANCER

Award Number: R43CA130275
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2007
PERIOD OF PERFORMANCE END DATE: 09/14/2008

Group Awards By:

View Award Description

DIGITAL GENE EXPRESSION FOR CANCER - DESCRIPTION (provided by applicant): Although precise knowledge of the genomic sequence within neoplastic tissues can be an indicator for treatment, for example the erbB-2 receptor gene (Her-2) for breast cancer, such correlations are few and often do not adequately define tumor subtypes important in therapeutic decisions. Such inability to identify a subclass of tumors which may not respond to standard therapies can restrict the development of more efficacious treatment strategies. The analysis of gene expression represents an indirect measure of the genetic alterations in tumors through the analysis of regulatory pathways. Microarray technologies have proven to be powerful tools and offer the promise of better clinical decision-making based on tumor phenotypes. Highly promising preliminary studies of leukemia, lymphomas, and solid neoplasms demonstrate that gene expression data can highlight differences between otherwise histological identical diseases. However, microarray-based technologies are limited in their ability to analyze low expression levels. We propose the use of a unique sequencing by synthesis technology as a digital gene expression system to obtain precise counts of expressed mRNA molecules. This has the promise of providing an order of magnitude more sensitivity than microarray systems. In this Phase I project, a new method for sample preparation which takes advantage of highly parallel sequencing technology is proposed. Ultimately, the ability to produce very inexpensive detailed DNA sequence information for complex organisms' genomes will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2007 ( Subtotal = $153,481 )
2007	2007	INTELLIGENT BIO-SYSTEMS INC	25 ROLLING LANE	WESTON	MA	02493	MIDDLESEX	USA	Cancer Biology Research	000	1	9/14/2007	NEW	$153,481
														Subtotal = $153,481

Grand Total All Awards = $153,481

Top

All Categories

About

Search

Reports

Data Submission

Award Information

DIGITAL GENE EXPRESSION FOR CANCER

Award Number: R43CA130275

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2007

PERIOD OF PERFORMANCE END DATE: 09/14/2008

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer